inotuzumab ozogamicin
pfizer,ucb pharmaceuticals
['leusm', '#all ,(-alli),(-allogenic)', 'inotuzumab', 'inotuzumab ozogamicin']
#eha2023 | presents real-world study on post-#hsct outcomes in #all pts receiving prior inotuzumab ozogamicin. 18-mo os was 54% &amp; nrm was 22%. common aes were bacterial infection (51%), viral infection (44%) &amp; grade 2-4 acute #gvhd (43%)
#allsm #leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm